| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 107.80 | 7.5% | 20.4% |
| Total Income | 107.80 | 7.5% | 20.4% |
| Expenditure | 73.22 | 42.1% | 11.4% |
| PBT | 97.82 | 34.7% | 1328.0% |
| Net Profit | 89.91 | 41.2% | 7330.6% |
| OPM | 32.08% | 16.54pp | |
| NPM | 83.40% | 19.90pp | 82.05pp |
| EPS | 1.30 | 28.7% | 6400.0% |
Innoviva Reports Q3 2025 Financial Results; Revenue $107.8M, Up 20% YoY
04 May 2026 · 4 May, 8:00 am
Summary
Innoviva reported strong third-quarter performance with total revenue of $107.8 million, a 20% increase compared to the same period last year. Royalty revenue grew by 5% to $63.4 million, while net product sales increased by 52% in the U.S. to $29.9 million. The company's net income significantly improved to $89.9 million, or $1.30 per share, compared to $1.2 million, or $0.02 per share, in the third quarter of 2024. Innoviva also announced a $125 million share repurchase program, reflecting confidence in the company's future prospects.
Key Highlights
- 1
Innoviva reported total revenue of $107.8 million for the third quarter of 2025, representing a 20% increase compared to $89.5 million in the third quarter of 2024.
- 2
Gross royalty revenue from Glaxo Group Limited was $63.4 million in Q3 2025, compared to $60.5 million in Q3 2024, reflecting a 5% growth.
- 3
Net product sales for Q3 2025 totaled $47.3 million, including $29.9 million in U.S. net product sales, a 52% increase compared to $19.7 million in Q3 2024.
- 4
Income from operations for Q3 2025 was $34.6 million, a 20% decrease from $43.2 million in Q3 2024, primarily due to a non-recurring expense related to research and development.
- 5
Net income for Q3 2025 was $89.9 million, or $1.30 basic per share, compared to a net income of $1.2 million, or $0.02 basic per share, for Q3 2024.
- 6
The company announced a $125 million share repurchase program, underscoring confidence in Innoviva’s prospects.
- 7
Innoviva's portfolio of strategic assets was valued at $483.0 million as of September 30, 2025.
Management Comments
Pavel Raifeld
“Innoviva delivered strong third-quarter performance across each area of our business. The royalties portfolio reaffirmed its resilience with 5% growth compared to last year, while IST delivered a third consecutive quarter of greater than 50% year-over-year U.S. sales growth. We are encouraged by early market receptivity for ZEVTERA® following its U.S. launch over the summer and look forward to zoliflodacin’s December 15 PDUFA date.” “Across the broader portfolio, we saw meaningful value creation from our strategic investments, including Armata Pharmaceuticals, and continued to thoughtfully deploy capital in areas of opportunity and market dislocation. The $125 million share repurchase program underscores our confidence in Innoviva’s prospects, supported by the strength of our balance sheet and cashflows, as we strive to create value for our shareholders,”
Informational and educational content only. Not investment advice.